{
    "hands_on_practices": [
        {
            "introduction": "The challenge of liquid biopsy is fundamentally one of detecting a 'needle in a haystack.' This first exercise provides a quantitative foundation by tasking you with a core calculation: estimating the absolute number of mutant DNA copies present in a small CSF sample. By working through this problem , you will translate abstract clinical parameters like cfDNA concentration and tumor fraction into the tangible reality of the few molecules that assays must successfully identify.",
            "id": "4490462",
            "problem": "A pediatric patient with medulloblastoma is undergoing a liquid biopsy via cerebrospinal fluid (CSF). You are asked to estimate the expected number of mutant copies of a clonal single-nucleotide variant detectable in the CSF, prior to any extraction or assay losses. The CSF sample volume is $2$ mL, and the total cell-free deoxyribonucleic acid (cfDNA) concentration is $3$ ng/mL. The fraction of cfDNA derived from the tumor (tumor fraction) is $0.005$. Assume the human haploid genome equivalent has a mass of $3.3$ pg, the mutation is clonal and heterozygous in a diploid tumor (so that within tumor-derived cfDNA the variant allele fraction is $0.5$), and that cfDNA molecules can be counted in haploid genome equivalents.\n\nStarting only from fundamental definitions of concentration ($m = C \\times V$), mass-per-genome equivalence, and the interpretation of expected counts as the product of total molecular counts and the probability that a molecule carries the mutation, compute the expected number of mutant copies present in the $2$ mL CSF sample.\n\nRound your answer to four significant figures. Express the final result as a number of copies (unitless count).",
            "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. All necessary data are provided, the values are physically realistic for a liquid biopsy analysis, and the question is posed in a way that allows for a unique, meaningful solution based on fundamental definitions.\n\nThe objective is to compute the expected number of mutant copies, denoted as $N_{mutant}$, in the given cerebrospinal fluid (CSF) sample. The calculation follows a logical sequence based on the provided data.\n\nFirst, we identify the given variables from the problem statement:\nThe CSF sample volume is $V = 2$ mL.\nThe total cell-free DNA (cfDNA) concentration is $C_{total} = 3$ ng/mL.\nThe fraction of cfDNA derived from the tumor (tumor fraction) is $\\text{TF} = 0.005$.\nThe mass of a human haploid genome equivalent is $m_{hGE} = 3.3$ pg.\nThe variant allele fraction (VAF) within tumor-derived cfDNA is $\\text{VAF}_{tumor} = 0.5$.\n\nThe first step is to calculate the total mass of cfDNA, $m_{total}$, in the sample. This is the product of the concentration $C_{total}$ and the volume $V$.\n$$m_{total} = C_{total} \\times V$$\nSubstituting the given values:\n$$m_{total} = 3 \\text{ ng/mL} \\times 2 \\text{ mL} = 6 \\text{ ng}$$\n\nNext, we calculate the mass of cfDNA derived from the tumor, $m_{tumor}$. This is the total mass of cfDNA, $m_{total}$, multiplied by the tumor fraction, $\\text{TF}$.\n$$m_{tumor} = m_{total} \\times \\text{TF}$$\nUsing the result from the previous step:\n$$m_{tumor} = 6 \\text{ ng} \\times 0.005 = 0.03 \\text{ ng}$$\n\nThen, we convert the mass of tumor-derived cfDNA into the number of tumor-derived haploid genome equivalents (hGE), denoted as $N_{hGE, tumor}$. This requires dividing the mass $m_{tumor}$ by the mass of a single haploid genome equivalent, $m_{hGE}$. For unit consistency, we must convert the mass of ctDNA from nanograms (ng) to picograms (pg), using the conversion factor $1 \\text{ ng} = 1000 \\text{ pg}$.\n$$m_{tumor, \\text{pg}} = 0.03 \\text{ ng} \\times \\frac{1000 \\text{ pg}}{1 \\text{ ng}} = 30 \\text{ pg}$$\nNow, we can calculate the number of tumor-derived haploid genome equivalents:\n$$N_{hGE, tumor} = \\frac{m_{tumor, \\text{pg}}}{m_{hGE}} = \\frac{30 \\text{ pg}}{3.3 \\text{ pg/hGE}}$$\n\nFinally, we calculate the expected number of mutant copies, $N_{mutant}$. This is the total number of tumor-derived haploid genome equivalents, $N_{hGE, tumor}$, multiplied by the probability that any given haploid genome equivalent carries the mutation. This probability is the VAF within the tumor-derived cfDNA, $\\text{VAF}_{tumor}$, which is given as $0.5$ for a clonal heterozygous mutation.\n$$N_{mutant} = N_{hGE, tumor} \\times \\text{VAF}_{tumor}$$\n$$N_{mutant} = \\left(\\frac{30}{3.3}\\right) \\times 0.5$$\n\nFor completeness, we can combine all steps into a single expression:\n$$N_{mutant} = \\frac{C_{total} \\times V \\times \\text{TF}}{m_{hGE}} \\times \\text{VAF}_{tumor}$$\nSubstituting the numerical values and including the unit conversion factor ($1000 \\text{ pg/ng}$):\n$$N_{mutant} = \\frac{(3 \\text{ ng/mL}) \\times (2 \\text{ mL}) \\times 0.005}{3.3 \\text{ pg/hGE}} \\times \\left(\\frac{1000 \\text{ pg}}{1 \\text{ ng}}\\right) \\times 0.5$$\nPerforming the arithmetic, where all units cancel to yield a dimensionless count:\n$$N_{mutant} = \\frac{3 \\times 2 \\times 0.005 \\times 1000}{3.3} \\times 0.5 = \\frac{30}{3.3} \\times 0.5$$\n$$N_{mutant} \\approx 9.090909... \\times 0.5 \\approx 4.545454...$$\nThe problem requires the final answer to be rounded to four significant figures.\n$$N_{mutant} \\approx 4.545$$\nThus, the expected number of mutant copies is approximately $4.545$.",
            "answer": "$$\\boxed{4.545}$$"
        },
        {
            "introduction": "Detecting a genetic variant is only the first step; correctly attributing its origin is the critical second. This practice presents a common and challenging diagnostic dilemma where a signal detected in CSF could originate from the brain tumor or from a benign blood-related phenomenon known as clonal hematopoiesis. By analyzing variant allele frequencies across matched blood and CSF samples , you will learn to apply principles of compartmental biology to distinguish a true tumor-derived signal from a systemic confounder.",
            "id": "4490535",
            "problem": "A patient with a radiographically suspected primary malignant glioma undergoes liquid biopsy as part of a research protocol. Targeted error-corrected next-generation sequencing with Unique Molecular Identifier (UMI) barcodes is performed on matched samples: plasma cell-free Deoxyribonucleic Acid (cfDNA), cerebrospinal fluid (CSF) cfDNA, and peripheral blood leukocyte genomic Deoxyribonucleic Acid (DNA) used as the matched normal. A single-nucleotide variant is observed at variant allele frequencies (VAFs) of $0.4\\%$ in plasma cfDNA and $0.02\\%$ in CSF cfDNA. The same variant is detected in matched leukocyte DNA at a VAF of $0.5\\%$. There is no prior tumor tissue available for comparison.\n\nUsing only fundamental definitions and well-established biological facts about cfDNA biogenesis and compartmental shedding in neuro-oncology, classify the most likely origin of this variant and justify the classification pattern in terms of source contribution and compartmental barriers. Choose the single best option.\n\n- A. Clonal hematopoiesis of indeterminate potential (CHIP)–derived hematopoietic variant; the similar VAFs in leukocyte DNA ($0.5\\%$) and plasma cfDNA ($0.4\\%$) and the very low CSF VAF ($0.02\\%$) are consistent with a hematopoietic clone contributing variant-bearing cfDNA to plasma, with trace carry-over into CSF rather than a brain tumor source.\n- B. Tumor-derived variant from the intracranial lesion; the higher plasma VAF ($0.4\\%$) relative to the CSF VAF ($0.02\\%$) indicates preferential systemic shedding, and the leukocyte VAF ($0.5\\%$) reflects circulating tumor material within leukocytes.\n- C. Germline heterozygous variant; the presence of the variant in leukocyte DNA at $0.5\\%$ VAF indicates constitutional carriage at low level, which explains detection in both plasma and CSF.\n- D. Sequencing artifact confined to the CSF assay; the $0.02\\%$ CSF signal is within the error floor, and the plasma and leukocyte signals at $0.4\\%$ and $0.5\\%$ are unrelated background noise.\n- E. Subclonal central nervous system (CNS) tumor variant with limited CSF shedding but disproportionate plasma shedding; blood–brain barrier heterogeneity explains the $0.4\\%$ plasma VAF exceeding the $0.02\\%$ CSF VAF despite no hematopoietic contribution.",
            "solution": "The objective is to determine the origin of the observed variant by analyzing its variant allele frequency (VAF) across three key biological compartments: leukocyte DNA (the matched \"normal\"), plasma cfDNA, and CSF cfDNA.\n\n1.  **Leukocyte DNA Analysis:** The variant is detected in the patient's leukocyte DNA at a VAF of 0.5%. This finding is critical. A variant originating from the brain tumor would be absent in hematopoietic cells (VAF ≈ 0%). A standard germline (inherited) variant would be present at a VAF of approximately 50%. The observed 0.5% VAF is inconsistent with both scenarios. Instead, it is the classic signature of **clonal hematopoiesis of indeterminate potential (CHIP)**, a phenomenon where a somatic mutation occurs in a hematopoietic stem cell, leading to a clonal population of blood cells carrying the variant.\n\n2.  **Plasma cfDNA Analysis:** The VAF in plasma is 0.4%. Cell-free DNA in plasma is primarily derived from the turnover of hematopoietic cells. Therefore, the plasma VAF is expected to be very similar to the VAF in the source leukocyte population. The observed 0.4% in plasma is in excellent agreement with the 0.5% VAF in leukocytes, further supporting the conclusion that the variant originates from a hematopoietic clone (CHIP).\n\n3.  **CSF cfDNA Analysis:** The VAF in the CSF is only 0.02%. The central nervous system is separated from the systemic circulation by the blood-brain and blood-CSF barriers, which are highly restrictive to the passage of cfDNA. For a primary brain tumor, one would expect the VAF to be significantly *higher* in CSF than in plasma. The observed pattern—a VAF in CSF that is 20-fold lower than in plasma—is the opposite of what would be expected for a tumor-derived variant. This pattern is, however, perfectly consistent with a systemic (blood-derived) variant, where only a trace amount leaks from the blood into the CSF.\n\n**Conclusion:** The concordant VAFs in leukocytes and plasma, coupled with a dramatically lower VAF in CSF, provides a definitive pattern indicating the variant's origin is clonal hematopoiesis (CHIP), not the brain tumor.\n\nTherefore, option A provides the most accurate and comprehensive explanation.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "A powerful assay is only useful if its results can be reliably interpreted in a clinical context. This final practice moves from analytical validation to clinical utility, demonstrating how a test's real-world performance is measured by its predictive values. You will apply Bayes' theorem to calculate the positive and negative predictive values for a ctDNA assay , highlighting the crucial interplay between a test's intrinsic accuracy and the prevalence of disease in the patient population.",
            "id": "4490454",
            "problem": "A hospital neuro-oncology service is evaluating a cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) assay for surveillance of glioblastoma recurrence. In a defined post-treatment surveillance cohort, the prevalence of true molecular recurrence is $p=0.20$. The ctDNA assay has sensitivity $s=0.85$ and specificity $c=0.95$. Using only the core definitions of sensitivity and specificity and Bayes’ theorem from probability theory, derive expressions for the positive predictive value (PPV) and negative predictive value (NPV) in terms of $s$, $c$, and $p$, and then compute their numerical values for the given parameters. Report PPV as $P(\\text{disease} \\mid \\text{test positive})$ and NPV as $P(\\text{no disease} \\mid \\text{test negative})$. Round each value to four significant figures and express them as decimals (do not use a percent sign). Provide the final answer in the order PPV then NPV as a single row matrix $\\begin{pmatrix}\\text{PPV} & \\text{NPV}\\end{pmatrix}$.",
            "solution": "We begin from core definitions. Let $D$ denote the event that disease (true molecular recurrence) is present, and let $T^{+}$ and $T^{-}$ denote positive and negative test results, respectively. The prevalence is $p=P(D)$, hence $P(\\neg D)=1-p$. Sensitivity is defined as $s=P(T^{+}\\mid D)$ and specificity is defined as $c=P(T^{-}\\mid \\neg D)$. By the law of total probability,\n$$\nP(T^{+}) \\;=\\; P(T^{+}\\mid D)P(D) + P(T^{+}\\mid \\neg D)P(\\neg D) \\;=\\; s\\,p + (1-c)(1-p),\n$$\nsince $P(T^{+}\\mid \\neg D)=1-c$. Bayes’ theorem gives\n$$\n\\text{PPV} \\;=\\; P(D\\mid T^{+}) \\;=\\; \\frac{P(T^{+}\\mid D)P(D)}{P(T^{+})} \\;=\\; \\frac{s\\,p}{s\\,p + (1-c)(1-p)}.\n$$\nSimilarly, for the negative predictive value,\n$$\nP(T^{-}) \\;=\\; P(T^{-}\\mid D)P(D) + P(T^{-}\\mid \\neg D)P(\\neg D) \\;=\\; (1-s)p + c(1-p),\n$$\nand Bayes’ theorem yields\n$$\n\\text{NPV} \\;=\\; P(\\neg D\\mid T^{-}) \\;=\\; \\frac{P(T^{-}\\mid \\neg D)P(\\neg D)}{P(T^{-})} \\;=\\; \\frac{c(1-p)}{(1-s)p + c(1-p)}.\n$$\nThese are the general expressions. We now substitute the given values $s=0.85$, $c=0.95$, and $p=0.20$.\n\nFor PPV:\n$$\ns\\,p = 0.85 \\times 0.20 = 0.17,\\quad (1-c)(1-p) = 0.05 \\times 0.80 = 0.04,\n$$\nso\n$$\n\\text{PPV} = \\frac{0.17}{0.17 + 0.04} = \\frac{0.17}{0.21} = \\frac{17}{21} \\approx 0.809523\\ldots.\n$$\nRounded to four significant figures as a decimal (no percent sign), this is $0.8095$.\n\nFor NPV:\n$$\nc(1-p) = 0.95 \\times 0.80 = 0.76,\\quad (1-s)p = 0.15 \\times 0.20 = 0.03,\n$$\nso\n$$\n\\text{NPV} = \\frac{0.76}{0.03 + 0.76} = \\frac{0.76}{0.79} = \\frac{76}{79} \\approx 0.962025\\ldots.\n$$\nRounded to four significant figures as a decimal, this is $0.9620$.\n\nTherefore, the final answer in the required order as a single row matrix is $\\begin{pmatrix}0.8095 & 0.9620\\end{pmatrix}$.",
            "answer": "$$\\boxed{\\begin{pmatrix}0.8095 & 0.9620\\end{pmatrix}}$$"
        }
    ]
}